Last reviewed · How we verify

aspirin + clopidogrel + celecoxib — Competitive Intelligence Brief

aspirin + clopidogrel + celecoxib (aspirin + clopidogrel + celecoxib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combination with NSAID. Area: Cardiovascular.

marketed Antiplatelet agent combination with NSAID COX-1, P2Y12 receptor, COX-2 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

aspirin + clopidogrel + celecoxib (aspirin + clopidogrel + celecoxib) — Seoul National University Hospital. This combination inhibits platelet aggregation through multiple pathways (cyclooxygenase and P2Y12 receptor blockade) while also reducing inflammation via COX-2 inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
aspirin + clopidogrel + celecoxib TARGET aspirin + clopidogrel + celecoxib Seoul National University Hospital marketed Antiplatelet agent combination with NSAID COX-1, P2Y12 receptor, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combination with NSAID class)

  1. Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aspirin + clopidogrel + celecoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-clopidogrel-celecoxib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: